DEA Places Insomnia Drug Into Schedule IV
The Drug Enforcement Administration is placing the newly approved drug Quiviviq (daridorexant) in Schedule IV of the Controlled Substances Act, it said in an interim final rule. Effective April 7, daridorexant, which was granted FDA approval in January, is subject…
Sign up for a free preview to unlock the rest of this article
Export Compliance Daily combines U.S. export control news, foreign border import regulation and policy developments into a single daily information service that reliably informs its trade professional readers about important current issues affecting their operations.
to new registration, labeling, record-keeping, and import and export requirements. DEA is accepting comments on the rule until May 9.